Maurie Markman

892 total citations
27 papers, 682 citations indexed

About

Maurie Markman is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, Maurie Markman has authored 27 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Reproductive Medicine, 11 papers in Surgery and 9 papers in Obstetrics and Gynecology. Recurrent topics in Maurie Markman's work include Ovarian cancer diagnosis and treatment (20 papers), Intraperitoneal and Appendiceal Malignancies (10 papers) and Endometrial and Cervical Cancer Treatments (8 papers). Maurie Markman is often cited by papers focused on Ovarian cancer diagnosis and treatment (20 papers), Intraperitoneal and Appendiceal Malignancies (10 papers) and Endometrial and Cervical Cancer Treatments (8 papers). Maurie Markman collaborates with scholars based in United States and Canada. Maurie Markman's co-authors include Gertrude Peterson, Alexander Kennedy, Jerome L. Belinson, Barbara Kulp, Stephen C. Rubin, Mark F. Brady, Nick M. Spirtos, P. Hanjani, J BELINSON and Keith A. Webster and has published in prestigious journals such as Journal of Clinical Oncology, Gynecologic Oncology and International Journal of Gynecology & Obstetrics.

In The Last Decade

Maurie Markman

26 papers receiving 662 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maurie Markman United States 14 505 356 184 180 79 27 682
W. Schroeder Germany 11 476 0.9× 294 0.8× 205 1.1× 156 0.9× 88 1.1× 18 651
Birgit Volgger Austria 11 371 0.7× 214 0.6× 134 0.7× 257 1.4× 82 1.0× 17 644
Robert Rothman United States 8 542 1.1× 299 0.8× 173 0.9× 248 1.4× 87 1.1× 14 809
A Kobierska Poland 10 558 1.1× 391 1.1× 272 1.5× 117 0.7× 33 0.4× 23 687
C. Coens Netherlands 3 624 1.2× 271 0.8× 344 1.9× 155 0.9× 44 0.6× 6 673
Malkasian Gd United States 16 495 1.0× 227 0.6× 228 1.2× 121 0.7× 96 1.2× 33 739
T. Latief United Kingdom 12 173 0.3× 326 0.9× 156 0.8× 160 0.9× 34 0.4× 14 529
M Markman United States 9 329 0.7× 214 0.6× 108 0.6× 145 0.8× 39 0.5× 15 436
Karishma Mehra United States 10 336 0.7× 123 0.3× 158 0.9× 93 0.5× 134 1.7× 11 578
Decker Dg United States 12 375 0.7× 154 0.4× 191 1.0× 136 0.8× 76 1.0× 22 598

Countries citing papers authored by Maurie Markman

Since Specialization
Citations

This map shows the geographic impact of Maurie Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maurie Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maurie Markman more than expected).

Fields of papers citing papers by Maurie Markman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maurie Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maurie Markman. The network helps show where Maurie Markman may publish in the future.

Co-authorship network of co-authors of Maurie Markman

This figure shows the co-authorship network connecting the top 25 collaborators of Maurie Markman. A scholar is included among the top collaborators of Maurie Markman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maurie Markman. Maurie Markman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Markman, Maurie. (2008). Strategies to examine new compounds for intraperitoneal use in ovarian cancer. International Journal of Gynecological Cancer. 18. 33–35. 5 indexed citations
2.
Micha, John P., Bram H. Goldstein, Mark A. Rettenmaier, et al.. (2006). Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma. International Journal of Gynecological Cancer. 16(3). 1147–1151. 5 indexed citations
3.
4.
Markman, Maurie, et al.. (2004). Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecologic Oncology. 93(2). 390–393. 31 indexed citations
5.
6.
Markman, Maurie, et al.. (2004). Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer. Gynecologic Oncology. 93(3). 715–717. 7 indexed citations
7.
8.
Markman, Maurie. (2003). Are we winning or losing the war on cancer?. Cleveland Clinic Journal of Medicine. 70(7). 632–633. 1 indexed citations
9.
Markman, Maurie, Alexander Kennedy, & Julian Kim. (2001). Potential Clinical Utility of CA-125 in Responsive but Persistent Large-Volume Ovarian Cancer Following Platinum-Based Chemotherapy:. Gynecologic Oncology. 83(3). 593–595. 1 indexed citations
10.
Smith, Simon A., William E. Richards, Parviz Hanjani, et al.. (2001). BRCA1 Germline Mutations and Polymorphisms in a Clinic-Based Series of Ovarian Cancer Cases: A Gynecologic Oncology Group Study. Gynecologic Oncology. 83(3). 586–592. 22 indexed citations
11.
12.
Markman, Maurie, et al.. (2000). Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer. Gynecologic Oncology. 79(1). 116–119. 54 indexed citations
13.
Markman, Maurie, Alexander Kennedy, Kenneth Webster, et al.. (1999). Persistent Chemosensitivity to Platinum and/or Paclitaxel in Metastatic Endometrial Cancer. Gynecologic Oncology. 73(3). 422–423. 11 indexed citations
14.
Berek, J. S., Maurie Markman, John A. Blessing, et al.. (1999). Intraperitoneal α-Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study. Gynecologic Oncology. 74(1). 48–52. 25 indexed citations
15.
Markman, Maurie, Mark F. Brady, Nick M. Spirtos, P. Hanjani, & Stephen C. Rubin. (1998). Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.. Journal of Clinical Oncology. 16(8). 2620–2624. 110 indexed citations
16.
Markman, Maurie, Alexander Kennedy, Gregory P. Sutton, et al.. (1998). Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent. Gynecologic Oncology. 70(2). 272–274. 38 indexed citations
17.
Markman, Maurie, John A. Blessing, David A. Moore, Harrison Ball, & Samuel S. Lentz. (1998). Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial. Gynecologic Oncology. 69(3). 226–229. 58 indexed citations
18.
Markman, Maurie. (1996). Should Cost Be Considered in the Overall Evaluation of Phase II Clinical Trials of New Antineoplastic Therapies?. Cancer Investigation. 14(5). 498–500. 2 indexed citations
19.
Fennelly, D., Carolyn Wasserheit, Juliane Schneider, et al.. (1994). Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.. PubMed. 54(23). 6137–42. 13 indexed citations
20.
Barakat, Richard R., Stephen C. Rubin, Patricia E. Saigo, et al.. (1991). Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube. Gynecologic Oncology. 42(2). 156–160. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Schroeder Breakdown of academic impact, for papers by Birgit Volgger Breakdown of academic impact, for papers by Robert Rothman Breakdown of academic impact, for papers by A Kobierska Breakdown of academic impact, for papers by C. Coens Breakdown of academic impact, for papers by Malkasian Gd Breakdown of academic impact, for papers by T. Latief Breakdown of academic impact, for papers by M Markman Breakdown of academic impact, for papers by Karishma Mehra Breakdown of academic impact, for papers by Decker Dg
Rankless by CCL
2026